Exact Sciences announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients. The initiative expands the collection of data accessible to Mayo Clinic researchers and clinicians to advance cancer research and patient care. Specialists at Mayo Clinic Comprehensive Cancer Center care for more than 130,000 unique cancer patients each year at three Mayo Clinic Comprehensive Cancer Center sites across the United States: Rochester, Minnesota and the Upper Midwest: Phoenix and Scottsdale, Arizona; and Jacksonville, Florida. Having access to the results from Exact Sciences’ comprehensive genomic profiling test and hereditary cancer test aims to help guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Citi opens ‘positive catalyst watch’ on Exact Sciences after competitor data
- Canaccord positive on Exact, Guardant after Freenome data
- Exact Sciences, Guardant rally after Freenome colorectal cancer test results
- Unusually active option classes on open April 2nd
- Exact Sciences’ Oncoguard Esophagus test shows efficacy in published study
